MétaCan
Menu
← Back to cohort
Record W2808767859 · doi:10.1093/neuonc/noy059.175

EAPH-06. HYPERMUTANT PEDIATRIC HIGH GRADE GLIOMAS ARE DRIVEN BY RAS/MAPK MUTATIONS AND RESPOND TO MEK INHIBITION

2018· article· en· W2808767859 on OpenAlexaff
Brittany Campbell, Daniel A. Morgenstern, Tatiana Lipman, David Fabrizio, Adam Shlien, Éric Bouffet, Cynthia Hawkins, Uri Tabori

Bibliographic record

VenueNeuro-Oncology · 2018
Typearticle
Languageen
FieldMedicine
TopicGlioma Diagnosis and Treatment
Canadian institutionsHospital for Sick Children
Fundersnot available
KeywordsTrametinibSelumetinibMAPK/ERK pathwayMedicineCancer researchMEK inhibitorMutationBiologySignal transductionGeneticsGene

Abstract

fetched live from OpenAlex

Hypermutant pediatric high grade gliomas (pHGG) constitute 5–10% of PHGG and are almost invariantly caused by replication repair deficiency (RRD). Constitutive activation of the RAS/MAPK pathway via oncogenic mutations can be targeted with MEK inhibitors (MEKi). We hypothesized that hypermutant RRD PHGG would harbor mutations in NF1 and other MAPK pathway regulators, making their tumors susceptible to MEKi. Tumor sequencing data from >1200 pediatric tumors was extracted from our foundation-medicine cohort. Exome and RNA-seq was performed on tumors from our international RRD consortium. Xenografts from patient derived pHGG were established in NOD-SCID mice and treated with Trametinib and Selumetinib. Functional experiments were performed to demonstrate deregulation of the MAPK pathway in the tumors. Screening of 1215 cancers revealed that RAS/MAPK mutations are the second most common mutation in pediatric tumors. Exome data from patients revealed 95% of PHGG were found to harbor mutations in key RAS/MAPK pathway regulators. Subclonal analysis reveals mutations in the pathway in each subclone and enrichment of these mutations over time. In-vitro and in-vivo treatment of patient derived RRD hypermutant PHGG with MEKi revealed significant tumor suppression with a 50% decrease in tumor volume and improved survival (p <0.001). Finally, two patients with progressive/recurrent PHGG treated with Selumetinib and trametinib exhibited >90% objective tumor response and prolonged survival. These preclinical and clinical observations suggest a novel therapeutic option for children with hypermutant RRD PHGG based on possible oncogenic addiction to RAS/MAPK alterations. These observations are the basis of the upcoming SU2C international clinical trial.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.292
Teacher spread0.274 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-Oncology→Same topicGlioma Diagnosis and Treatment→French-language works237,207→